May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 22, 2025

New AAP Guidelines Refresh Atopic Dermatitis Care

Applying topicals 2 to 3 times per week to previously affected areas—even when the skin appears clear—can reduce flare frequency and improve quality of life.

Conexiant

May 19, 2025

Zyrtec and Xyzal: FDA Issues Withdrawal Syndrome Warning

A new safety alert highlights the potential for severe itch following discontinuation of long-term cetirizine and levocetirizine use.

Conexiant

May 06, 2025

Combo Therapy Shows Repigmentation Gains in Vitiligo

Ritlecitinib alone or with nbUVB therapy led to significant improvements in skin repigmentation among vitiligo patients, with more pronounced effects seen when both treatments were combined, according to a new phase 2b study.

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

April 09, 2025

Study: Langerhans Cells Key to Diagnosing Contact Dermatitis

A case-control study of 170 biopsied dermatitis cases found that Langerhans cell collections were significantly more common in allergic contact dermatitis than in nonallergic cases.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

April 28, 2025

Delgocitinib Cream Outperforms Alitretinoin in Trial

Topical delgocitinib improved eczema severity scores and caused fewer adverse events than oral alitretinoin in adults with severe chronic hand eczema, according to a phase 3 study.

Conexiant